» Articles » PMID: 2996503

Calpain Inhibition by Peptide Epoxides

Overview
Journal Biochem J
Specialty Biochemistry
Date 1985 Sep 1
PMID 2996503
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

A Ca2+-activated cysteine proteinase (calpain II) was purified from chicken gizzard smooth muscle by use of isoelectric precipitation, (NH4)2SO4 fractionation, chromatography on DEAE-Sepharose CL-6B, Reactive-Red 120-agarose and Mono Q. The apparent second-order rate constants for the inactivation of calpain by a series of structural analogues of L-3-carboxy-trans-2, 3-epoxypropionyl-leucylamido-(4-guanidino)butane (E-64) were determined. The fastest rate of inactivation was observed with L-3-carboxy-trans-2, 3-epoxypropionyl-leucylamido-(4-benzyloxy-carbonylamino)buta ne. It was possible to determine the active-site molarity of solutions of calpain by titration with E-64. When incubated with Ca2+, calpain underwent several steps of intermolecular limited proteolysis, via multiple pathways, followed by a slower loss of enzymic activity. The proteolytic steps preceding the loss of activity did not affect the rates of reaction of calpain with E-64 analogues.

Citing Articles

Structure determinants defining the specificity of papain-like cysteine proteases.

Petushkova A, Savvateeva L, Zamyatnin Jr A Comput Struct Biotechnol J. 2022; 20:6552-6569.

PMID: 36467578 PMC: 9712828. DOI: 10.1016/j.csbj.2022.11.040.


Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors.

Fan W, Zhang W, Alshehri S, Garrison J Eur J Med Chem. 2022; 234:114241.

PMID: 35306289 PMC: 9007894. DOI: 10.1016/j.ejmech.2022.114241.


Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.

Fan W, Zhang W, Alshehri S, Neeley T, Garrison J Eur J Med Chem. 2019; 177:386-400.

PMID: 31158752 PMC: 6636858. DOI: 10.1016/j.ejmech.2019.05.068.


Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Siklos M, BenAissa M, Thatcher G Acta Pharm Sin B. 2015; 5(6):506-19.

PMID: 26713267 PMC: 4675809. DOI: 10.1016/j.apsb.2015.08.001.


Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate.

Hook G, Jacobsen J, Grabstein K, Kindy M, Hook V Front Neurol. 2015; 6:178.

PMID: 26388830 PMC: 4557097. DOI: 10.3389/fneur.2015.00178.


References
1.
Waxman L . Calcium-activated proteases in mammalian tissues. Methods Enzymol. 1981; 80 Pt C:664-80. DOI: 10.1016/s0076-6879(81)80051-1. View

2.
Barrett A, Kembhavi A, Brown M, KIRSCHKE H, Knight C, Tamai M . L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J. 1982; 201(1):189-98. PMC: 1163625. DOI: 10.1042/bj2010189. View

3.
Mellgren R, Repetti A, Muck T, Easly J . Rabbit skeletal muscle calcium-dependent protease requiring millimolar CA2+. Purification, subunit structure, and Ca2+-dependent autoproteolysis. J Biol Chem. 1982; 257(12):7203-9. View

4.
Hathaway D, Werth D, Haeberle J . Limited autolysis reduces the Ca2+ requirement of a smooth muscle Ca2+-activated protease. J Biol Chem. 1982; 257(15):9072-7. View

5.
Zimmerman U, SCHLAEPFER W . Characterization of a brain calcium-activated protease that degrades neurofilament proteins. Biochemistry. 1982; 21(17):3977-82. DOI: 10.1021/bi00260a012. View